格隆汇2月19日丨EPS创健科技(03860.HK)公告,于2025年2月19日,公司(作为卖方)与买方(为公司的控股股东)订立买卖协议,据此,公司有条件同意出售而买方有条件同意收购目标公司EPS Innovative Medicine(Hong Kong)Limited的全部已发行股本,代价为1.00日圆。根据买卖协议,公司亦有条件同意出售或促使出售而买方有条件同意收购销售贷款(即目标公司与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.